logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

XBiotech Inc.

XBIT

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, orā€¦ read more

Healthcare

Biotechnology

11 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$2.23

Price

-0.45%

-$0.01

$2.24

Previous Close

$2.23

Open

Premium

52w Discount
Market Cap

$67.988m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-25.0%

5y CAGR
Earnings

-$40.161m

+11.8%

1y CAGR

-21.1%

3y CAGR

-9.5%

5y CAGR
EPS

-$1.32

+11.4%

1y CAGR

-20.8%

3y CAGR

-9.3%

5y CAGR
Book Value

$135.017m

$139.836m

Assets

$4.819m

Liabilities

-

Debt
Debt to Assets

0.0%

-

Debt to EBITDA
Free Cash Flow

-$42.364m

-5.4%

1y CAGR

-33.0%

3y CAGR

-30.7%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.